Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Liu JW
------>authors3_c=
------>paper_class1=1
------>Impact_Factor=7.920
------>paper_class3=2
------>paper_class2=1
------>vol=166
------>confirm_bywho=ncchang
------>insert_bywho=yungching
------>Jurnal_Rank=7.8
------>authors4_c=
------>comm_author=
------>patent_EDate=None
------>authors5_c=
------>publish_day=1
------>paper_class2Letter=None
------>page2=2123
------>medlineContent=
------>unit=E0109
------>insert_date=20090312
------>iam=7
------>update_date=None
------>author=???
------>change_event=4
------>ISSN=
------>authors_c=
------>score=500
------>journal_name=Arch Intern Med
------>paper_name=Prognostic factors and antibiotics in Vibrio vulnificus septicemia.
------>confirm_date=20090313
------>tch_id=097070
------>pmid=17060542
------>page1=2117
------>fullAbstract=BACKGROUND: Immunocompromised patients with Vibrio vulnificus septicemia are at high risk for fatality. When a hemorrhagic bullous necrotic cutaneous lesion (HBNCL) and decreased blood pressure develop, approximately 50% of V vulnificus septicemic patients die within 48 hours. This study aimed to evaluate the risk factor(s) for fatality among patients with V vulnificus septicemia, emphasizing the role of prescribed antimicrobial agents in general and the therapeutic efficacy of the combination of a third-generation cephalosporin and tetracycline or its analogue in particular. METHODS: Patients with the diagnosis of V vulnificus infection admitted to 5 large medical centers in Taiwan between 1995 and 2003 were included in this retrospective study. Patients were divided into 2 groups: those without [corrected] HBNCLs (group 1) [corrected] and those with [corrected] HBNCLs (group 2) [corrected]Patients were further divided into subgoups with [corrected] fatalities (fatal subgroup) and those without fatalities (nonfatal subgroup). RESULTS: A total of 93 patients participated in the study. In group 1, the fatal subgroup had higher Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (P = .006) and a higher proportion of shock at arrival at the medical center (P = .015) than the nonfatal subgroup. In group 2, the effect of a first- or second-generation cephalosporin plus an aminoglycoside was negative (P = .01) and that of combined third-generation cephalosporin and tetracycline or its analogue was positive (P<.001); significant differences were found between the fatal and nonfatal subgroups in the APACHE II score (P<.001), number who were in shock at arrival at the medical center (P = .02), delayed surgical intervention (P = .03), and peripheral leukocytosis (P = .03). Shock at arrival at the medical center (odds ratio [OR], 19.25; 95% confidence interval [CI], 1.768-209.54; P = .02) was an independent risk factor for fatality in patients without HBNCLs. Use of a third-generation cephalosporin and tetracycline or its analogue significantly reduced fatality rates in patients with HBNCLs (OR, 0.037; 95% CI, 0.007-0.192; P<.001). CONCLUSION: Septic shock is a determinant of fatality in patients with V vulnificus septicemia without HBNCLs; our data suggest that the combination of a third-generation cephalosporin and tetracycline or its analogue may be a better choice in antimicrobial treatment of V vulnificus septicemic patients with HBNCLs.
------>tmu_sno=None
------>sno=21412
------>authors2=Lee IK
------>authors3=Tang HJ
------>authors4=Ko WC
------>authors5=Lee HC
------>authors6=Liu YC, Hsueh PR, Chuang YC
------>authors6_c=
------>authors=Liu JW
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=
------>publish_area=0
------>updateTitle=Prognostic factors and antibiotics in Vibrio vulnificus septicemia.
------>language=2
------>check_flag=None
------>submit_date=None
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=2006
------>submit_flag=None
------>publish_month=1
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z